As the US sees its highest number of measles cases in decades and vaccination rates fall, researchers are developing drugs to help those who contract the virus or who are particularly vulnerable. Up until recently, measles vaccination has been so effective that there's been little medical or financial incentive to develop treatments for the disease. But as measles cases hit a 35-year high and vaccination rates continue to decline in the US, a handful of biotech companies and academic groups have started working on measles treatments for those infected with the virus as well as vulnerable individuals needing short-term protection. It will likely be years, however, before these countermeasures are available, and it's even more uncertain if those who refuse vaccines would take such treatments. Fueled by large outbreaks in South Carolina and Utah, the US had already surpassed last year's 2,289 measles cases, and it's only July.

Environment Animals Wildlife Endangered Species Koala nicknamed'teddy bear' receives first chlamydia vaccine implant The implant delivers the vaccine's second dose without having to recapture the koala. More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. Bamse the koala returns to the wild after receiving the first chlamydia vaccine implant. Breakthroughs, discoveries, and DIY tips sent six days a week. By signing up, you confirm you are 16+, will receive newsletters and promotional content and agree to our Terms of Use and acknowledge the data practices in our Privacy Policy .

A meningitis B (MenB) vaccination programme targeting young people and university students in Northern Ireland will roll out from 31 July, NI's chief medical officer has said. It follows an outbreak in England earlier this year, in which two people - a university student and a sixth-form pupil - died. The two-dose vaccine will be offered to those deemed most at risk from the infection, including Year 14 students and under-25s starting university or a Higher Education institution for the first time this autumn. MenB is a bacterial infection that can cause serious, life-threatening illness including inflammation of the lining of the brain and blood poisoning (sepsis). It is spread by close contact such as kissing, sharing vapes or drinks, or living in close quarters - like student accommodation - with a person who has the disease.

High street pharmacies across England are now offering a free meningitis B vaccine for many young people. It comes after concerns over the UK's largest and fastest growing outbreak that happened in Kent earlier this year. So who needs the vaccine and what's in it? What's the vaccine and is it safe? The vaccine offers protection against a dangerous strain of meningitits called meningitis B (MenB) that caused the outbreak in Kent. The vaccine does not contain any live bacteria and cannot cause meningitis.

Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens.

A man gets his Covid and flu vaccine shot at Boston city hall on 7 January 2026. A man gets his Covid and flu vaccine shot at Boston city hall on 7 January 2026. Adults in the US who frequently seek out health advice from artificial intelligence chatbots are more likely to believe myths about vaccines, according to a poll released on Tuesday by health research firm KFF. The survey, which was conducted in May and polled a representative sample of 2,480 US adults, found that use of AI tools and chatbots correlated with belief in falsehoods such as vaccines causing autism or that the measles vaccine poses more danger than the corresponding virus. The connection remained while controlling for factors such as age, race, education and political partisanship.

Years after initial tests, researchers are now racing to see if a vaccine developed in 2011 can help fight the current Bundibugyo outbreak in Congo. Fever was the first symptom to grip the crab-eating macaques in their high-containment laboratory on an island off Texas after being infected with the newly discovered Bundibugyo strain of ebola . Then came the weight loss, the rectal bleeding and nosebleeds, while scientists in space suits drew blood to see how the monkeys' immune systems struggled to fight the aggressive virus. But the three monkeys that had received a newly developed vaccine to protect against the understudied strain showed no symptoms of the disease, which eventually killed two-thirds of their unvaccinated companions. It was 2011, and virologist Thomas Geisbert's work developing the vaccine was done.

The DeceptionBench is designed as a research benchmark to systematically study deception behaviors in LLMs, fostering a deeper understanding of their decision-making processes in real-world scenarios. Our primary intent is to provide a standardized, transparent tool for the research community to evaluate and improve LLMs' ethical alignment, not to enable or encourage deceptive practices. To prevent potential misuse by malicious actors, we commit to publicly releasing all evaluation data under an open license. This transparency ensures that DeceptionBench's methodology and outcomes are subject to scrutiny, replication, and improvement by the research community, reducing the risk of hidden exploitation. By prioritizing openness, we aim to advance responsible AI development while safeguarding against misuse in harmful contexts. The field of Large Language Models (LLMs) has undergone remarkable evolution in recent years, reshaping the landscape of natural language processing.

Despite the remarkable advances of Large Language Models (LLMs) across diverse cognitive tasks, the rapid enhancement of these capabilities also introduces emergent deception behaviors that may induce severe risks in high-stakes deployments. More critically, the characterization of deception across realistic real-world scenarios remains underexplored. To bridge this gap, we establish DeceptionBench, the first benchmark that systematically evaluates how deceptive tendencies manifest across different societal domains, what their intrinsic behavioral patterns are, and how extrinsic factors affect them. Specifically, on the static count, the benchmark encompasses 150 meticulously designed scenarios in five domains, i.e., Economy, Healthcare, Education, Social Interaction, and Entertainment, with over 1,000 samples, providing sufficient empirical foundations for deception analysis. On the intrinsic dimension, we explore whether models exhibit self-interested egoistic tendencies or sycophantic behaviors that prioritize user appeasement. On the extrinsic dimension, we investigate how contextual factors modulate deceptive outputs under neutral conditions, reward-based incentivization, and coercive pressures. Moreover, we incorporate sustained multi-turn interaction loops to construct a more realistic simulation of real-world feedback dynamics. Extensive experiments across LLMs and Large Reasoning Models (LRMs) reveal critical vulnerabilities, particularly amplified deception under reinforcement dynamics, demonstrating that current models lack robust resistance to manipulative contextual cues and the urgent need for advanced safeguards against various deception behaviors.

An AI-designed universal vaccine targeting a broad range of coronaviruses passed its first clinical trial, proving safe and triggering an immune response in 39 healthy volunteers.